Cellectis S.A.
NASDAQ:CLLSBiotechnology
-$0.02 today
- Market cap
- $106.78M
- Beta
- 2.75
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$0.67
Volume 0.02M
Average 0.04M
CLLS EPS (Basic)
Net income attributable to common shareholders divided by the weighted average basic shares outstanding.
Cellectis S.A.NASDAQ: CLLS
EPS (Basic) · Q1 FY2026 · quarter ended Mar 2026
EPS (Basic) remains negative
Q1 FY2026 EPS (Basic) was -$0.18, compared with -$0.18 a year earlier. Trailing-twelve-month EPS (Basic) was -$0.68.
Context
- EPS (Basic) grew in size in 1 of the last 3 fiscal years.
What to watch
Whether EPS (Basic) reaches the consensus estimate from 1 analysts of -$1.21 (-78.1%) for the fiscal year ending Dec 2026, a slowdown from the -65.9% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$0.18+33.3% QoQ
- Last fiscal yearDec 2025
- -$0.68-65.9% YoY
- LTMMar 2026
- -$0.68-8.4% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +0.0% | -9.6% | -9.6 pp |
| 1 year | -65.9% | -78.1% | -12.3 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EPS (Basic) history
USD · from the income statement
- Latest · FY2025
- (0.68) USD
- Year-over-year change
- -65.9%
| Period | Period end | EPS (Basic) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (0.68) | -65.9% |
| FY2024 | 2024-12-31 | (0.41) | +76.8% |
| FY2023 | 2023-12-31 | (1.77) | +24.0% |
| FY2022 | 2022-12-31 | (2.33) | -20.7% |
| FY2021 | 2021-12-31 | (1.93) | — |
EPS (Basic) vs competitors
How CLLS compares with its peers on the latest reported figures
- Peers report in different currencies, so EPS (Basic) is compared through growth and rates rather than absolute size.
- Its year-over-year change of -8.4% is the 5th highest of 10, against a peer median of -23.7%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | -$0.22 USD | +99.9% | — | |
| LTM Mar 2026 | -$0.46 USD | +52.9% | — | |
| LTM Mar 2026 | -CHF 0.66 CHF | -32.0% | — | |
| LTM Mar 2026 | -$0.67 USD | -42.8% | — | |
| LTM Mar 2026 | -$0.68 USD | -8.4% | — | |
| LTM Mar 2026 | -$1.62 USD | +62.1% | — | |
| LTM Mar 2026 | -$1.93 USD | -63.6% | — | |
| LTM Mar 2026 | -$2.1 USD | -40.9% | — | |
| LTM Mar 2026 | -$2.48 USD | -6.4% | — | |
| LTM Mar 2026 | -$4.32 USD | — | — | |
| LTM Mar 2026 | -$11.68 USD | -23.7% | — | |
| Peer median (excluding CLLS) | — | -23.7% | — | |
Competitors are the stored peer set for CLLS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 30.35M | 19.17M | 755K | 41.51M | 72.95M |
| Cost of Revenue | 1.84M | 8.48M | 7.42M | 9.18M | 9.8M |
| Gross Profit | 28.5M | 10.69M | (6.66M) | 32.32M | 63.15M |
| Gross Margin | 93.9% | 55.7% | -882.6% | 77.9% | 86.6% |
| Research & Development | 117.84M | 97.5M | 87.65M | 90.54M | 93.52M |
| Selling, General & Admin | 22.88M | 8.9M | 8.12M | 8.42M | 8.6M |
| Operating Expenses | 131.98M | 100.35M | 90.64M | 91.88M | 96.23M |
| Depreciation & Amortization | 14.16M | 18.44M | 18.52M | 19.85M | 20.06M |
| EBITDA | (78.43M) | (76.38M) | (92.64M) | (9.46M) | (39.85M) |
| EBITDA Margin | -258.4% | -398.4% | -12269.8% | -22.8% | -54.6% |
| Operating Income | (103.48M) | (89.67M) | (97.3M) | (59.55M) | (33.08M) |
| Operating Margin | -341.0% | -467.7% | -12887.7% | -143.5% | -45.3% |
| Interest Income | 719K | 1.12M | 3.61M | 11.28M | 9.5M |
| Interest Expense | 4.37M | 3.79M | 5.31M | 7.45M | 8.11M |
| Other Income / Expenses | 6.73M | (8.94M) | (19.16M) | 22.79M | (34.94M) |
| Income Before Tax | (96.75M) | (98.6M) | (116.46M) | (36.76M) | (68.02M) |
| Pre-Tax Margin | -318.8% | -514.3% | -15425.7% | -88.6% | -93.2% |
| Income Tax Expense | (3K) | 87K | 371K | 0 | (423K) |
| Net Income | (114.2M) | (106.14M) | (101.06M) | (36.76M) | (67.59M) |
| Net Margin | -376.3% | -553.6% | -13385.3% | -88.6% | -92.7% |
| EPS (Basic) | (1.93) | (2.33) | (1.77) | (0.41) | (0.68) |
| EPS (Diluted) | (1.93) | (2.33) | (1.77) | (0.41) | (0.68) |
| Weighted Avg Shares | 44.82M | 45.55M | 57.01M | 90.57M | 100.28M |
| Weighted Avg Shares (Diluted) | 44.82M | 45.55M | 57.01M | 90.57M | 100.28M |
Cellectis S.A.
NASDAQ:CLLS
Intrinsic Alpha fair value
Locked
Current Price
$1.06
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.